ELISA II研究PPT课件.ppt

《ELISA II研究PPT课件.ppt》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、ELISAIITrialPresentedatTheEuropeanSocietyofCardiologyHotLineSession2005PresentedbyDr.SamanRasoulELISAIITrialDualanti-plateletstrategywithaspirinandhigh-doseclopidogrel(600mgload)n=166ELISAIITrialPresentedatESC2005Tripleanti-plateletstrategywithaspirin,standard-doseclopidogrel(300mgload),andti

2、rofiban(10μg/kgbolusfollowedby0.15μg/kginfusion)n=162328patientswithnon-STelevationMI;ischemicchestpainatrestwithin24hrs;andeitherpositivebiomarkers(CKMBortroponin)oranabnormalECG(STdepression>0.1mVin>2leadsortransientSTelevation)29%female,meanage63years,meanfollow-up30daysLow-molecularweight

3、heparin,beta-blocker,andstatintherapywereadministeredtoallpatientsPrimaryEndpoint:InfarctsizeasassessedbyLDHQat48hoursandasassessedbypeakCKSecondaryEndpoint:InitialTIMIflowgradeoftheculpritarteryAngiographywithorwithoutrevascularization(24-48hrs)ELISAIITrial:BaselineCharacteristicsMediantimet

4、oangiographyPresentedatESC2005Inthedualtherapygroup,mediantimetoangiographywas26hours.Inthetripletherapygroup,mediantimetoangiographywas30hrs.81%ofenrolledpatientshadapositivetroponinand62%hadSTdepressionPCIwasperformedin~60%ofpatientsELISAIITrial:PrimaryEndpointAnalysisofinfarctsizewhenasses

5、sedbyLDHQp=0.36PresentedatESC2005TheprimaryendpointofinfarctsizedidnotdifferbetweenthedualtherapygroupandthetripletherapygroupwhenassessedbyLDHQ(p=0.36)orpeakCK(p=NS)392331ELISAIITrial:SecondaryEndpointAnalysisofinitialTIMIgrade3flowatangiography(%)p=0.002PresentedatESC2005Thesecondaryendpoin

6、tofinitialTIMIgrade3flowatangiographywashigherinthetripletherapygroup(47%vs67%)ELISAIITrial:MIFreeSurvivalat30daysAnalysisofsurvivalfreefrommyocardialinfarctionat30days(%)p=0.098PresentedatESC2005Atrendtowardhigherratesofsurvivalfreefrommyocardialinfarctionat30dayswereobservedinthetriplethera

7、pygroupTheseresultsweredrivenalmostexclusivelybymyocardialinfarction(56%MIrateinthedualtherapygroupvs46%MIrateinthetripletherapygroup)Mortalityrateof1%ineachgroupELISAIITrial:BleedingAnalysisofbleeding(%)PresentedatESC2005Nosignificantdiffere